These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17994110)

  • 1. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.
    Yao BB; Hsieh GC; Frost JM; Fan Y; Garrison TR; Daza AV; Grayson GK; Zhu CZ; Pai M; Chandran P; Salyers AK; Wensink EJ; Honore P; Sullivan JP; Dart MJ; Meyer MD
    Br J Pharmacol; 2008 Jan; 153(2):390-401. PubMed ID: 17994110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
    Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
    Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.
    Chin CL; Tovcimak AE; Hradil VP; Seifert TR; Hollingsworth PR; Chandran P; Zhu CZ; Gauvin D; Pai M; Wetter J; Hsieh GC; Honore P; Frost JM; Dart MJ; Meyer MD; Yao BB; Cox BF; Fox GB
    Br J Pharmacol; 2008 Jan; 153(2):367-79. PubMed ID: 17965748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
    Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
    J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
    Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
    Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?
    Yao BB; Mukherjee S; Fan Y; Garrison TR; Daza AV; Grayson GK; Hooker BA; Dart MJ; Sullivan JP; Meyer MD
    Br J Pharmacol; 2006 Sep; 149(2):145-54. PubMed ID: 16894349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
    Han S; Thoresen L; Zhu X; Narayanan S; Jung JK; Strah-Pleynet S; Decaire M; Choi K; Xiong Y; Yue D; Semple G; Thatte J; Solomon M; Fu L; Whelan K; Al-Shamma H; Gatlin J; Chen R; Dang H; Pride C; Gaidarov I; Unett DJ; Behan DP; Sadeque A; Usmani KA; Chen C; Edwards J; Morgan M; Jones RM
    Bioorg Med Chem Lett; 2015 Jan; 25(2):322-6. PubMed ID: 25488844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
    Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
    Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
    Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
    Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
    Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
    Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB
    Li AL; Carey LM; Mackie K; Hohmann AG
    J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
    Zhu CZ; Mikusa JP; Fan Y; Hollingsworth PR; Pai M; Chandran P; Daza AV; Yao BB; Dart MJ; Meyer MD; Decker MW; Hsieh GC; Honore P
    Br J Pharmacol; 2009 Jun; 157(4):645-55. PubMed ID: 19371344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.
    Khasabova IA; Gielissen J; Chandiramani A; Harding-Rose C; Odeh DA; Simone DA; Seybold VS
    Behav Pharmacol; 2011 Sep; 22(5-6):607-16. PubMed ID: 21610490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.
    Ibrahim MM; Deng H; Zvonok A; Cockayne DA; Kwan J; Mata HP; Vanderah TW; Lai J; Porreca F; Makriyannis A; Malan TP
    Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10529-33. PubMed ID: 12917492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
    Rahn EJ; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
    Quartilho A; Mata HP; Ibrahim MM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
    Anesthesiology; 2003 Oct; 99(4):955-60. PubMed ID: 14508331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
    Brownjohn PW; Ashton JC
    Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain.
    Li MH; Suchland KL; Ingram SL
    J Neurosci; 2017 Jan; 37(3):626-636. PubMed ID: 28100744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.